| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (NCT01849276) | Northwestern University | 2015-03-11 |
| MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02049801) | Bruno C. Medeiros | 2014-12-01 |
| Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy (NCT02071901) | Case Comprehensive Cancer Center | 2014-08-14 |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02029417) | Roswell Park Cancer Institute | 2014-07-01 |
| Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02030405) | Steven E. Coutre | 2014-03-01 |
| AML Therapy With Irradiated Allogeneic Cells (NCT02105116) | Rutgers, The State University of New Jersey | 2014-02-01 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01904643) | Stanford University | 2014-02-01 |
| Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (NCT01831232) | Fred Hutchinson Cancer Center | 2013-05-01 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01835288) | Stanford University | 2013-05-01 |
| Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01820624) | Paolo Caimi, MD | 2013-04-30 |
| Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01822015) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-03-15 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (NCT01801046) | University of Southern California | 2013-03-06 |
| Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS (NCT01607645) | Fred Hutchinson Cancer Center | 2012-07-01 |
| Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia (NCT01839240) | University of Chicago | 2012-06-06 |
| Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT01550185) | Roswell Park Cancer Institute | 2012-05-01 |
| Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy (NCT01521936) | Roswell Park Cancer Institute | 2011-12-01 |
| Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission (NCT01465386) | Fred Hutchinson Cancer Center | 2011-11-01 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (NCT01555268) | Roswell Park Cancer Institute | 2011-10-31 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (NCT01427881) | Fred Hutchinson Cancer Center | 2011-09-01 |
| Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01342887) | Fred Hutchinson Cancer Center | 2011-04-01 |
| Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01349972) | National Cancer Institute (NCI) | 2011-04-01 |
| Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02085408) | ECOG-ACRIN Cancer Research Group | 2011-02-04 |
| Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy (NCT01235572) | Fred Hutchinson Cancer Center | 2010-12-01 |
| AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01253447) | National Cancer Institute (NCI) | 2010-10-01 |
| Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (NCT01127009) | Case Comprehensive Cancer Center | 2010-07-01 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia (NCT01159301) | National Cancer Institute (NCI) | 2010-06-01 |
| Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (NCT01031368) | Nohla Therapeutics, Inc. | 2009-12-01 |
| Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML (NCT00895934) | National Cancer Institute (NCI) | 2009-05-01 |
| Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia (NCT02144675) | Rutgers, The State University of New Jersey | 2009-01-01 |
| Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00795002) | National Cancer Institute (NCI) | 2008-11-01 |
| Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00634244) | National Cancer Institute (NCI) | 2008-10-01 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia (NCT00602771) | National Cancer Institute (NCI) | 2008-01-01 |
| Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01093586) | Case Comprehensive Cancer Center | 2007-09-01 |
| MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (NCT00462605) | National Cancer Institute (NCI) | 2007-04-01 |
| Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia (NCT00470197) | National Cancer Institute (NCI) | 2007-04-01 |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia (NCT00352365) | National Cancer Institute (NCI) | 2006-06-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes (NCT00301938) | National Cancer Institute (NCI) | 2005-12-01 |
| Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00131989) | National Cancer Institute (NCI) | 2005-06-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00112853) | National Cancer Institute (NCI) | 2005-03-01 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes (NCT00098826) | National Cancer Institute (NCI) | 2004-12-01 |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (NCT00098423) | National Cancer Institute (NCI) | 2004-11-01 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00101296) | National Cancer Institute (NCI) | 2004-10-01 |
| XK469R in Treating Patients With Refractory Hematologic Cancer (NCT00095797) | National Cancer Institute (NCI) | 2004-10-01 |
| Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00096148) | National Cancer Institute (NCI) | 2004-10-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00101231) | National Cancer Institute (NCI) | 2004-10-01 |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00096122) | National Cancer Institute (NCI) | 2004-09-01 |
| S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (NCT00093418) | National Cancer Institute (NCI) | 2004-09-01 |
| Cilengitide in Treating Patients With Acute Myeloid Leukemia (NCT00089388) | National Cancer Institute (NCI) | 2004-07-01 |
| Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission (NCT00045435) | Fred Hutchinson Cancer Center | 2002-04-01 |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00027872) | National Cancer Institute (NCI) | 2001-10-01 |
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (NCT00006363) | National Cancer Institute (NCI) | 2000-11-01 |
| Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00003190) | National Cancer Institute (NCI) | 1998-01-01 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |